XML 44 R22.htm IDEA: XBRL DOCUMENT
v3.25.0.1

EMPLOYEE BENEFIT PLANS | 12 Months Ended
--- | ---
Dec. 31, 2024
Retirement Benefits [Abstract] |
EMPLOYEE BENEFIT PLANS | EMPLOYEE BENEFIT PLANS Employee Savings Plan We have defined contribution retirement savings plans covering eligible associates which include matching contributions based on the amount of our associates’ contributions to the plans. The cost of these plans amounted to approximately $293 million in 2024, $278 million in 2023, and $286 million in 2022. The Company’s cash match is invested pursuant to the participant’s contribution direction. Based on the closing price of our common stock of $253.71 on December 31, 2024, approximately 4% of the retirement and savings plan’s assets were invested in our common stock, or approximately 1.1 million shares, representing approximately 0.9% of the shares outstanding as of December 31, 2024. At December 31, 2024, approximately 5.3 million shares of our common stock were reserved for issuance under our defined contribution retirement savings plans. Stock-Based Compensation We have plans under which options to purchase our common stock and restricted stock units have been granted to executive officers, directors and key associates. Awards generally require both a change in control and termination of employment within 2 years of the date of the change in control to accelerate the vesting, including those granted to retirement-eligible participants. The terms and vesting schedules for stock-based awards vary by type of grant. Generally, the awards vest upon time-based conditions. We have also granted awards to certain associates that vest upon a combination of time and performance-based conditions. The stock awards of retirement-eligible participants are generally earned ratably over the service period for each tranche. Accordingly, upon retirement the earned portion of the current tranche will continue to vest on the originally scheduled vest date and any remaining unearned portion of the award will be forfeited. Our equity award program includes a retirement provision that generally treats associates with a combination of age and years of services with the Company totaling 65 or greater, with a minimum required age of 55 and a minimum requirement of 5 years of service, as retirement-eligible. Upon exercise, stock-based compensation awards are settled with authorized but unissued company stock or treasury stock. The compensation expense that has been charged against income for these plans was as follows for the years ended December 31, 2024, 2023, and 2022:
| 2024 |  | 2023 |  | 2022
| (in millions)
Stock-based compensation expense by type: |  |  |  |  |
Restricted stock | $ | 198 |  |  | $ | 168 |  |  | $ | 207 |
Stock options | 9 |  |  | 7 |  |  | 9 |
Total stock-based compensation expense | 207 |  |  | 175 |  |  | 216 |
Tax benefit recognized | (29) |  |  | (28) |  |  | (28) |
Stock-based compensation expense, net of tax | $ | 178 |  |  | $ | 147 |  |  | $ | 188 |
The tax benefit recognized in our consolidated financial statements is based on the amount of compensation expense recorded for book purposes, subject to limitations on the deductibility of annual compensation in excess of $500,000 per employee as mandated by the Health Care Reform Law. The actual tax benefit realized in our tax return is based on the intrinsic value, or the excess of the market value over the exercise or purchase price, of stock options exercised and restricted stock vested during the period, subject to limitations on the deductibility of annual compensation in excess of $500,000 per employee as mandated by the Health Care Reform Law. The actual tax benefit realized for the deductions taken on our tax returns from option exercises and restricted stock vesting totaled $21 million in 2024, $30 million in 2023, and $31 million in 2022. There was no capitalized stock-based compensation expense during these years. At December 31, 2024, there were approximately 11.0 million shares reserved for stock award plans under the Humana Inc. 2011 Stock Incentive Plan, or 2011 Plan, and approximately 14.3 million shares reserved for stock award plans under the Humana Inc. 2019 Stock Incentive Plan, or 2019 Plan. These reserved shares included giving effect to, under the 2011 Plan, 3.3 million shares of common stock available for future grants assuming all stock options were granted or 1.4 million shares available for future grants assuming all restricted stock were granted. These reserved shares included giving effect to, under the 2019 Plan, 7.5 million shares of common stock available for future grants assuming all stock options were granted or 2.2 million shares available for future grants assuming all restricted stock were granted. Shares may be issued from authorized but unissued company stock or treasury stock. Restricted Stock Restricted stock is granted with a fair value equal to the market price of our common stock on the date of grant and generally vests in equal annual tranches over a three year period from the date of grant. Certain of our restricted stock grants also include performance-based conditions generally associated with return on invested capital and strategic membership growth. Restricted stock units have forfeitable dividend equivalent rights equal to the dividend paid on common stock. The weighted-average grant date fair value of our restricted stock was $364.59 in 2024, $508.23 in 2023, and $430.06 in 2022. Activity for our restricted stock was as follows for the year ended December 31, 2024:
| Shares |  | Weighted- Average Grant-Date Fair Value
| (shares in thousands)
Nonvested restricted stock at December 31, 2023 | 754 |  |  | $ | 488.06 |
Granted | 686 |  |  | 364.59 |
Vested | (497) |  |  | 389.41 |
Forfeited | (75) |  |  | 433.72 |
Nonvested restricted stock at December 31, 2024 | 868 |  |  | $ | 426.40 |
Approximately 33% of the nonvested restricted stock at December 31, 2024 included performance-based conditions. The fair value of shares vested was $157 million during 2024, $236 million during 2023, and $244 million during 2022. Total compensation expense not yet recognized related to nonvested restricted stock was $221 million at December 31, 2024. We expect to recognize this compensation expense over a weighted-average period of approximately 1.7 years. There are no other contractual terms covering restricted stock once vested. Stock Options Stock options are granted with an exercise price equal to the fair market value of the underlying common stock on the date of grant. Our stock plans, as approved by the Board of Directors and stockholders, define fair market value as the average of the highest and lowest stock prices reported on the composite tape by the New York Stock Exchange on a given date. Exercise provisions vary, but most options vest in whole or in part 1 to 3 years after grant and expire 7 years after grant. The weighted-average fair value of each option granted during 2024, 2023, and 2022 is provided below. The fair value was estimated on the date of grant using the Black-Scholes pricing model with the weighted-average assumptions indicated below:
| 2024 |  | 2023 |  | 2022
Weighted-average fair value at grant date | $ | 96.42 |  |  | $ | 130.74 |  |  | $ | 113.35 |
Expected option life (years) | 3.5 years |  | 3.0 years |  | 3.6 years
Expected volatility | 28.8 | % |  | 31.6 | % |  | 36.1 | %
Risk-free interest rate at grant date | 4.3 | % |  | 4.5 | % |  | 1.8 | %
Dividend yield | 0.9 | % |  | 0.7 | % |  | 0.7 | %
We calculate the expected term for our employee stock options based on historical employee exercise behavior and base the risk-free interest rate on a traded zero-coupon U.S. Treasury bond with a term substantially equal to the option’s expected term. The volatility used to value employee stock options is based on historical volatility. We calculate historical volatility using a simple-average calculation methodology based on daily price intervals as measured over the expected term of the option. Activity for our option plans was as follows for the year ended December 31, 2024:
| Shares Under Option |  | Weighted-Average Exercise Price
| (shares in thousands)
Options outstanding at December 31, 2023 | 242 |  |  | $ | 415.18 |
Granted | 149 |  |  | 385.05 |
Exercised | (1) |  |  | 259.26 |
Forfeited | (15) |  |  | 391.61 |
Options outstanding at December 31, 2024 | 375 |  |  | $ | 404.61 |
Options exercisable at December 31, 2024 | 166 |  |  | $ | 393.73 |
As of December 31, 2024, outstanding stock options, substantially all of which are expected to vest, had no intrinsic value, and a weighted-average remaining contractual term of 4.5 years. As of December 31, 2024, exercisable stock options had no intrinsic value, and a weighted-average remaining contractual term of 3.1 years. The total intrinsic value of stock options exercised during 2024 was $0.1 million, compared with $3 million during 2023 and $32 million during 2022. Cash received from stock option exercises totaled $0.3 million in 2024, $9 million in 2023, and $51 million in 2022. Total compensation expense not yet recognized related to nonvested options was $14 million at December 31, 2024. We expect to recognize this compensation expense over a weighted-average period of approximately 1.8 years.

X
- Definition Disclosure Of Compensation Related Costs Share Based Payments And Compensation And Retirement Disclosure [Text Block] + References No definition available. + Details
Name: | hum_DisclosureOfCompensationRelatedCostsShareBasedPaymentsAndCompensationAndRetirementDisclosureTextBlock
Namespace Prefix: | hum_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_CompensationAndRetirementDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration